Emicizumab

Emicizumab (trade name Hemlibra) is a humanized bispecific antibody for the treatment of haemophilia A, developed by Genentech and Chugai (a subsidiary of Roche).[1] A Phase I clinical trial found that it was well tolerated by healthy subjects.[2] In November 2017, it was approved in the United States for treatment of haemophilia A in those who had developed resistance to other treatments.[3] It was subsequently approved by the US FDA in April 2... [wikipedia]